Expression of Ron and Met proto-oncogenes in epithelial ovarian cancer: Clinical implications;Valutazione dell'espressione dei proto-oncogeni Ron e Met nei tumori epiteliali ovarici

Minerva Ginecologica

Volumn 51, Issue 10, 1999, Pages 359-364

  Fracchioli, S ^a   Katsaros, D ^a   Maggiora, P ^a   Di Renzo, M F ^a   Massobrio, M ^a  

^a NONE

Author keywords

Met; Ovarian neoplasms; Proto oncogenes; Ron

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR;

ARTICLE; CARCINOMA; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; OVARY; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA; FEMALE; GENE EXPRESSION; HUMANS; OVARIAN NEOPLASMS; OVARY; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033201745     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992;44:207-12.
2. Fleischer AC, Cullinan JA. Peery CV. Jones HWr. Early detection of ovarian carcinoma with transvaginal color Doppler ultrasonography. Am J Obstet Gynecol 1996; 174:101-6.
3. Chang F. Syrjanen S. Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
4. Marx D. Meden H, Ziemek T, Lenthe T, Kuhn W Schauer A. Expression of the p53 tumor suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 1998;34:845-50.
5. Smith SA, Easton DF, Evans DG, Ponder BA. Allele losses in the region 17q 12-21 in familial breast and ovarian cancer involve ihe wild-type chromosome. Nat Genet 1992;2:128-31.
6. Jishi MF, Itnyre JH, Oakley-Girvan IA, Piver MS, Whittemore AS. Risks of cancer among members of families in the Gilda Radner Familial Ovarian Cancer Registry. Cancer 1995;76:1416-21.
7. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-5.
8. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
9. Medico E, Mongiovì AM, Huff J, Jelinek MA, Follenzi A, Gaudino G et al. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 1996;7:495-504.
10. Schmidt L. Duh FM, Chen F, Kishida T, Glenn G, Choyke P et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16: 68-73.
11. Gherardi E, Stoker M. Hepatocyte growth factor-scat-ter factor: mitogen, motogen and met. Cancer Cells 1991;3:227-32.
12. Maggioni P. Marchiò S, Stella MC. Overexpression of the RON gene in human breast cancer. Oncogene 1998;15:109-15.
13. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L et al. Overexpression and amplification of the Met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995;1:147-54.
14. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993;8:1195-202.
15. Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer 1994;58:658-62.
16. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol 1998;25:305-14.
17. Chen Q, Seol DV, Carr B, Zarnegar R. Co-expression and modulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 1997;26:59-66.